Drug Profile
Research programme: insulin analogues - Chongqing Peg-Bio Biotechnology/Jilin Sihuan Pharmaceutical
Alternative Names: Recombinant insulin aspart; Recombinant insulin degludec; Recombinant regular insulinLatest Information Update: 12 Oct 2023
Price :
$50
*
At a glance
- Originator Chongqing Peg-Bio Biotechnology
- Developer Jilin Sihuan Pharmaceutical
- Class Antihypercalcaemics; Insulins; Pancreatic hormones; Recombinant proteins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 12 Oct 2023 Discontinued - Preclinical for Diabetes mellitus in China (Parenteral) (Chongqing Peg-Bio Biotechnology website, October 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in China (Parenteral)
- 06 Sep 2018 Sihuan Pharmaceutical receives approval to conduct clinical trials for the long-acting insulin degludec